Atlas market file · Equity · United States
Medifast IncMED
- Last close
- 12.28
- Change
- -6.12%
- 96-bar range
- 9.39 – 13.45
- As of
- 5 Aug 2026
Medifast Inc is a miscellaneous food preparations & kindred products issuer listed as MED on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
MED
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-38.54% over the window).
Source rail: Yahoo Finance chart API (MED). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for MED. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
MED public profile
Miscellaneous food preparations & kindred products issuer. Medifast Inc is connected to current market context, cited company sources and its retained research file.
Medifast Inc trades as MED on NYSE. Medifast Inc (MED) has a latest verified close of 12.28, down 6.12%, dated 5 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files MED under USA Stocks for browsing.
What changed for Medifast Inc today
Medifast Inc reported revenue of $76 million for the quarter ended March 31 2026, but net income attributable to parent was negative $2.1 million, according to its 10-Q filing with the SEC. The company lost 19 cents per diluted share on 11 million shares outstanding, while operating income came in at negative $3.3 million. These are the hard numbers from the first quarter, filed on time and available on EDGAR.
Medifast sells weight loss products, programs and support, targeting metabolic dysfunction with clinically proven science and experienced coaches, according to its official website. The company has a significant cash cushion: $71.5 million in cash and equivalents plus $97.4 million in short term investments, against total liabilities of $54.4 million. Stockholders equity stands at $197.7 million, so the balance sheet is not the problem.
The first quarter 2026 earnings webcast and supplement are available on the investor relations page, alongside the press release announcing those results. Research and development spending was $4.3 million for the full year 2025, and inventory rose to $21.4 million at the end of the first quarter, up $1.2 million from the prior period. Cash from operations was just $260,000, while capital expenditure ran at $1.1 million.
A schedule 13G/A was filed on July 29 2026, indicating a significant holder adjusted their position. Two Form 4 filings from May 28 2026 show insider transactions, and an 8-K from July 17 2026 covers a material event. The SEC filings are the primary source for understanding the company's financial trajectory.
The evidence shows a company with a strong cash position but an earnings problem. Revenue is not growing fast enough to cover costs, and the operating loss suggests the core business is under pressure. The next quarterly filing will show whether the trend continues or reverses.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
MED technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on MED
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep MED research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
MED FAQ
What is Medifast Inc (MED)?Medifast Inc (MED) has a latest verified close of 12.28, down 6.12%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Medifast Inc (MED) has a latest verified close of 12.28, down 6.12%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for MED?Medifast Inc (MED) has a latest verified close of 12.28, down 6.12%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
Medifast Inc (MED) has a latest verified close of 12.28, down 6.12%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files MED under USA Stocks for browsing.
How often is the MED page updated?The MED public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The MED public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for MED?The MED file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:MED. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The MED file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:MED. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on MED?Yes. The workstation can open MED, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open MED, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this MED page investment advice?No. The MED page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The MED page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-30. Browse FreedomCore Atlas research notes →